Clinical Factors Associated with Body-weight Reduction Induced by Semaglutide 1.0 mg Weekly in Patients with Type 2 Diabetes Mellitus
Pretreatment HDL-cholesterol levels serve as important information for weekly treatment with 1.0 mg semaglutide in patients with T2DM and expectation of weight reduction.
Authors
- Keizo Kajiwara (ORCID: https://orcid.org/0000-0003-3779-1638)
- Fumio MIYAMOTO
- Masatoshi Nomura
- Kunio Hieshima
- Katsunori Jinnouchi
- Noboru Kurinami (ORCID: https://orcid.org/0000-0002-8381-4194)
- Seigo Sugiyama (ORCID: https://orcid.org/0000-0003-2494-0374)
- Akira Yoshida
- Kenji Ashida (ORCID: https://orcid.org/0000-0001-8753-6016)
- Hideaki Jinnouchi (ORCID: https://orcid.org/0000-0002-7391-7966)
- Tomoko Suzuki (ORCID: https://orcid.org/0000-0002-3986-8291)
- Masafumi Takada
Institutions
- Kurume University (JP)
- Kumamoto University Hospital (JP)
Publication Details
- Journal
- JMA Journal
- Published
- 2025-01-01
- DOI
- https://doi.org/10.31662/jmaj.2024-0366
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00